{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:50:01Z","timestamp":1790254201652,"version":"4.1.0"},"reference-count":0,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"published-print":{"date-parts":[[2018]]},"abstract":"<b><i>Background:<\/i><\/b> <sup>18<\/sup>F-FDOPA positron emission tomography\/computed tomography (PET\/CT) is a sensitive nuclear imaging technology for the diagnosis of pheochromocytomas (PHEO). However, its utility in determining predictive factors for the secretion of catecholamines remains poorly studied. <b><i>Methods:<\/i><\/b> Thirty-nine histologically confirmed PHEO were included in this retrospective single-center study. Patients underwent <sup>18<\/sup>F-FDOPA PET\/CT before surgery, with an evaluation of several uptake parameters (standardized uptake values [SUV<sub>max<\/sub> and SUV<sub>mean<\/sub>] and the metabolic burden [MB] calculated as follows: MB = SUV<sub>mean<\/sub> \u00d7 tumor volume) and measurement of plasma and\/or urinary metanephrine (MN), normetanephrine (NM), and chromogranin A. Thirty-five patients were screened for germline mutations in the <i>RET<\/i>, <i>SDHx<\/i>, and <i>VHL<\/i> genes. Once resected, primary cultures of 5 PHEO were used for real-time measurement of catecholamine release by carbon fiber amperometry. <b><i>Results:<\/i><\/b> The MB of the PHEO positively correlated with 24-h urinary excretion of NM (<i>r<\/i> = 0.64, <i>p<\/i> &#x3c; 0.0001), MN (<i>r<\/i> = 0.49, <i>p<\/i> = 0.002), combined MN and NM (<i>r<\/i> = 0.75, <i>p<\/i> &#x3c; 0.0001), and eventually plasma free levels of NM (<i>r<\/i> = 0.55, <i>p<\/i> = 0.006). In the mutated patients (3 <i>SDHD<\/i>, 2 <i>SDHB<\/i>, 3 <i>NF1<\/i>, 1 <i>VHL<\/i>, and 3 <i>RET<\/i>), a similar correlation was observed between MB and 24-h urinary combined MN and NM (<i>r<\/i> = 0.86, <i>p<\/i> = 0.0012). For the first time, we demonstrate a positive correlation between the PHEO-to-liver SUV<sub>max<\/sub> ratio and the mean number of secretory granule fusion events of the corresponding PHEO cells revealed by amperometric spikes (<i>p<\/i> = 0.01). <b><i>Conclusion:<\/i><\/b> While the <sup>18<\/sup>F-FDOPA PET\/CT MB of PHEO strongly correlates with the concentration of MN, amperometric recordings suggest that <sup>18<\/sup>F-FDOPA uptake could be enhanced by overactivity of catecholamine exocytosis.<\/jats:p>","DOI":"10.1159\/000491578","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T21:01:19Z","timestamp":1530133279000},"page":"228-236","source":"Crossref","is-referenced-by-count":17,"title":["18F-FDOPA PET\/CT Uptake Parameters Correlate with Catecholamine Secretion in Human Pheochromocytomas"],"prefix":"10.1159","volume":"107","author":[{"given":"Sophie","family":"Moog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Houy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Weryha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Rame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brunaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Gasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2018,6,27]]},"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/491578","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/491578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:46:47Z","timestamp":1745426807000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000491578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,8]]},"published-print":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.1159\/000491578","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}